The long-term follow-up of patients with uncontrolled, treatment-resistant hypertension, treated with renal denervation demonstrated larger and sustained reductions in SBP when compared with a sham procedure, as shown by the final results from the SYMPLICITY HTN-3 trial.

In patients with HFmrEF or HFpEF, the efficacy and safety of dapagliflozin were not influenced by background treatment with an MRA or ARNI, as shown by a prespecified analysis of the DELIVER trial.

A Dutch cross-sectional study showed that Lp(a) levels were higher and more often elevated in children with a clinical presentation of FH in whom no FH-causing mutation was detected compared with children with a mutation and their unaffected siblings.

European AF guidelines recommend treating patients with stable AF and an increased risk of stroke beyond 1 year after PCI with anticoagulant monotherapy, rather than dual therapy with an oral anticoagulant and antiplatelet drug. However, the evidence for this is scarce.

Prof. Leiter presents a case of a patient with high CV risk despite LDL-c lowering with statin therapy. He explains why this patient may benefit from treatment with icosapent ethyl.

Irrespective of a history of ASCVD, finerenone reduced the risk of CV events and CKD progression compared with placebo in patients with T2DM and CKD, as shown in a FIDELITY subgroup analysis.

A Norwegian nationwide cohort study showed that in newly diagnosed HF patients, 1-year adherence to dual or triple HF therapies was low and 2- to 5-year persistence was inadequate.

Mechanistic studies on plaque characteristics in patients receiving EPA can be insightful to understand the CV risk reductions seen in clinical trials. Prof. Budoff gives an overview of effects of EPA on multiple plaque components.

Sufficient physical activity lowers the risk of CV mortality and improves quality of life. However, little is known about the association between timing of physical activity and CVD risk in the general population.

In an ORION-11 substudy, inclisiran reduced LDL-c, non-HDL-c and apoB levels in a subgroup of high-risk patients with elevated LDL-c but without prior CV events receiving maximally tolerated statin therapy.

Finerenone, a non-steroidal MRA, has been approved for the treatment of CKD in adults with T2DM. Previously, the FIDELITY study showed that finerenone improves cardiorenal outcomes in these patients. But does this also apply to HF-related outcomes?

In 530 patients hospitalized for acute HF, empagliflozin treatment resulted in early, clinically meaningful decongestion compared with placebo. The magnitude of decongestion was associated with clinical benefit at day 90.